These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 9112331)

  • 41. Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines.
    Roth M; Block LH
    Thorax; 2000 Aug; 55(8):678-84. PubMed ID: 10899245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
    Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
    Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor.
    Hammacher A; Richardson RT; Layton JE; Smith DK; Angus LJ; Hilton DJ; Nicola NA; Wijdenes J; Simpson RJ
    J Biol Chem; 1998 Aug; 273(35):22701-7. PubMed ID: 9712900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The tyrosine 974 within the LIF-R-chain of the gp130/LIF-R heteromeric receptor complex mediates negative regulation of LIF signalling.
    Clahsen T; Lehmann U; Stross C; Hermanns HM; Volkmer-Engert R; Schneider-Mergener J; Heinrich PC; Schaper F
    Cell Signal; 2005 May; 17(5):559-69. PubMed ID: 15683731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. LIF and OM directly interact with a soluble form of gp130, the IL-6 receptor signal transducing subunit.
    Modrell B; Liu J; Miller H; Shoyab M
    Growth Factors; 1994; 11(2):81-91. PubMed ID: 7857660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biosynthetic and glycosylation events of the IL-6 receptor beta-subunit, gp130.
    Wang Y; Fuller GM
    J Cell Biochem; 1995 Apr; 57(4):610-8. PubMed ID: 7615645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes.
    Grötzinger J; Kurapkat G; Wollmer A; Kalai M; Rose-John S
    Proteins; 1997 Jan; 27(1):96-109. PubMed ID: 9037715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gp130 and the interleukin-6 family of cytokines.
    Taga T; Kishimoto T
    Annu Rev Immunol; 1997; 15():797-819. PubMed ID: 9143707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane.
    Schroers A; Hecht O; Kallen KJ; Pachta M; Rose-John S; Grötzinger J
    Protein Sci; 2005 Mar; 14(3):783-90. PubMed ID: 15722452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo.
    Saito M; Yoshida K; Hibi M; Taga T; Kishimoto T
    J Immunol; 1992 Jun; 148(12):4066-71. PubMed ID: 1602143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. gp130 signaling pathways: Recent advances and implications for cardiovascular disease.
    Hirota H; Yoshida K; Taga T; Kishimoto T
    Trends Cardiovasc Med; 1996 May; 6(4):109-15. PubMed ID: 21232283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human interleukin 4 receptor complex: neutralization effect of two monoclonal antibodies.
    Taremi SS; Prosise WW; Rajan N; O'Donnell RA; Le HV
    Biochemistry; 1996 Feb; 35(7):2322-31. PubMed ID: 8652573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interactions between oncostatin M and the IL-6 signal transducer, gp130.
    Liu J; Modrell B; Aruffo A; Scharnowske S; Shoyab M
    Cytokine; 1994 May; 6(3):272-8. PubMed ID: 8054483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
    Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
    Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors.
    Sporeno E; Paonessa G; Salvati AL; Graziani R; Delmastro P; Ciliberto G; Toniatti C
    J Biol Chem; 1994 Apr; 269(15):10991-5. PubMed ID: 8157624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A functional role of the membrane-proximal extracellular domains of the signal transducer gp130 in heterodimerization with the leukemia inhibitory factor receptor.
    Timmermann A; Küster A; Kurth I; Heinrich PC; Müller-Newen G
    Eur J Biochem; 2002 Jun; 269(11):2716-26. PubMed ID: 12047380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IL-6 antisense-mediated growth inhibition of a choriocarcinoma cell line: an intracellular autocrine growth mechanism.
    Kong B; Isozaki T; Sasaki S
    Gynecol Oncol; 1996 Oct; 63(1):78-84. PubMed ID: 8898173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M.
    Gu ZJ; Wijdenes J; Zhang XG; Hallet MM; Clement C; Klein B
    J Immunol Methods; 1996 Mar; 190(1):21-7. PubMed ID: 8601708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation.
    Pflanz S; Kurth I; Grötzinger J; Heinrich PC; Müller-Newen G
    J Immunol; 2000 Dec; 165(12):7042-9. PubMed ID: 11120832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies.
    Kalai M; Montero-Julian FA; Brakenhoff JP; Fontaine V; De Wit L; Wollmer A; Brailly H; Content J; Grötzinger J
    Eur J Biochem; 1997 Nov; 249(3):690-700. PubMed ID: 9395315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.